12:00 AM
 | 
Oct 07, 2013
 |  BioCentury  |  Finance

Altered Fate

Fate accepts IPO haircut, but now can reach Phase II inflection point
Altered Fate

After spooking investors by disclosing a clinical delay in its S-1, Fate Therapeutics Inc. (NASDAQ:FATE) decided to accept a drastically reduced price from what it has been seeking in exchange for a public listing and enough cash to turn over some important cards.

Fate's lead product is ProHema, hematopoietic stem cells derived from umbilical cord blood that is modulated with FT1050, a small molecule prostaglandin E2 analog.

The company began a Phase II trial...

Read the full 366 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >